Pickering T G
Cardiovascular Center, New York Hospital-Cornell University Medical Center, NY 10021.
Semin Nucl Med. 1989 Apr;19(2):79-88. doi: 10.1016/s0001-2998(89)80003-0.
Evidence from animal studies demonstrates that the renin-angiotensin (ANG II) system and sodium retention play major roles in experimental renovascular hypertension (RVH). Two basic models have been described. In the first, one-clip two-kidney Goldblatt hypertension, the ischemic kidney secretes renin, which leads to increased ANG II formation and hence elevation of blood pressure (BP). As BP rises, sodium excretion by the intact contralateral kidney increases (pressure natriuresis); therefore, there is no sodium retention. In the second, one-clip one-kidney Goldblatt hypertension, the contralateral kidney is removed. In this case the pressure natriuresis can no longer occur, and sodium retention occurs. The ensuing expansion of plasma volume inhibits renin secretion, so that in this model the renin level is normal or low. Following the clipping of the renal artery, renal blood flow and pressure are maintained distal to the stenosis by an ANG II-mediated vasoconstriction. This acts preferentially on the efferent glomerular arterioles, so that the ratio of preglomerular to postglomerular resistance is reduced, which helps to maintain glomerular filtration despite the reduced renal perfusion pressure. In the contralateral kidney the afferent arteriolar resistance is increased, probably as a direct result of exposure to the higher intrarenal arterial pressure. ANG II constricts the efferent arterioles in the same way as in the ischemic kidney, so that the ratio of preglomerular to postglomerular resistance is unchanged. When an angiotensin converting enzyme (ACE) inhibitor is given, the efferent arterioles vasodilate. In the ischemic kidney this may produce a reduction of glomerular filtration rate (GFR), which is not seen in the contralateral kidney. Unilateral RVH in humans corresponds closely to the animal model of one-clip two-kidney hypertension. Plasma renin activity is usually high, and converting enzyme inhibitors lower BP effectively. The increased renin is due exclusively to increased secretion of renin by the ischemic kidney, and is completely suppressed in the contralateral kidney. It is not clear whether bilateral RVH corresponds to the one-clip one-kidney model, but there is circumstantial evidence to suggest that both renin and volume factors may be involved. The majority of cases of human RVH are caused by atheroma, which is commonly bilateral, or by fibromuscular dysplasia. The former tends to be associated with atheroma elsewhere in the arterial tree, and often progresses to complete occlusion and renal failure. The latter occurs in younger patients, and almost never progresses to complete occlusion.
动物研究证据表明,肾素 - 血管紧张素(ANG II)系统和钠潴留在实验性肾血管性高血压(RVH)中起主要作用。已描述了两种基本模型。第一种是单夹双肾戈德布拉特高血压模型,缺血的肾脏分泌肾素,这导致ANG II生成增加,进而使血压(BP)升高。随着血压升高,完整的对侧肾脏的钠排泄增加(压力性利钠);因此,不存在钠潴留。第二种是单夹单肾戈德布拉特高血压模型,对侧肾脏被切除。在这种情况下,压力性利钠不再发生,钠潴留出现。随之而来的血浆容量扩张抑制肾素分泌,所以在这个模型中肾素水平正常或较低。肾动脉夹闭后,通过ANG II介导的血管收缩维持狭窄远端的肾血流量和压力。这优先作用于出球小动脉,使得入球小动脉与出球小动脉阻力之比降低,这有助于在肾灌注压降低的情况下维持肾小球滤过。在对侧肾脏,入球小动脉阻力增加,可能是直接暴露于较高的肾内动脉压的结果。ANG II以与缺血肾脏相同的方式收缩出球小动脉,使得入球小动脉与出球小动脉阻力之比不变。给予血管紧张素转换酶(ACE)抑制剂时,出球小动脉扩张。在缺血肾脏中,这可能导致肾小球滤过率(GFR)降低,而在对侧肾脏中则不会出现这种情况。人类单侧RVH与单夹双肾高血压的动物模型密切对应。血浆肾素活性通常较高,转换酶抑制剂能有效降低血压。肾素增加完全是由于缺血肾脏肾素分泌增加,而在对侧肾脏中则完全被抑制。双侧RVH是否与单夹单肾模型对应尚不清楚,但有间接证据表明肾素和容量因素可能都参与其中。人类RVH的大多数病例是由动脉粥样硬化引起的,动脉粥样硬化通常是双侧的,或者由纤维肌发育异常引起。前者往往与动脉树其他部位的动脉粥样硬化相关,并且常常进展为完全闭塞和肾衰竭。后者发生在较年轻的患者中,几乎从不进展为完全闭塞。